| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
34,395 |
31,588 |
$9.36M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
16,079 |
14,605 |
$6.15M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
24,742 |
23,040 |
$3.91M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
17,740 |
16,048 |
$575K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
18,089 |
16,452 |
$567K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
82,030 |
74,392 |
$412K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,402 |
4,146 |
$378K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
3,470 |
1,674 |
$312K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
11,364 |
9,328 |
$293K |
| 80053 |
Comprehensive metabolic panel |
56,830 |
49,982 |
$272K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12,048 |
11,070 |
$270K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
14,242 |
13,401 |
$268K |
| 86850 |
|
13,793 |
12,988 |
$207K |
| 84484 |
|
15,130 |
13,036 |
$192K |
| 71045 |
Radiologic examination, chest; single view |
16,158 |
14,711 |
$184K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
13,173 |
12,451 |
$175K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
11,822 |
9,720 |
$174K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
12,561 |
11,656 |
$161K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
51,005 |
44,712 |
$156K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
26,447 |
24,440 |
$148K |
| 59025 |
Fetal non-stress test |
1,914 |
1,591 |
$147K |
| G0378 |
Hospital observation service, per hour |
371 |
236 |
$124K |
| 84702 |
|
8,168 |
7,262 |
$121K |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,141 |
3,836 |
$112K |
| 86787 |
|
5,822 |
5,449 |
$106K |
| 86780 |
|
13,268 |
12,522 |
$104K |
| 86900 |
|
6,524 |
6,084 |
$103K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,244 |
1,159 |
$99K |
| 84144 |
|
5,355 |
4,931 |
$83K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,347 |
1,229 |
$78K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
9,941 |
9,377 |
$77K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,823 |
1,068 |
$74K |
| 83880 |
|
2,793 |
2,314 |
$68K |
| 43235 |
|
100 |
91 |
$67K |
| 82728 |
|
6,653 |
6,357 |
$65K |
| 86803 |
|
5,673 |
5,327 |
$65K |
| 83690 |
|
17,687 |
16,312 |
$65K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
9,943 |
8,840 |
$58K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
8,714 |
7,895 |
$51K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,082 |
3,819 |
$47K |
| 82951 |
|
4,292 |
4,085 |
$43K |
| 87276 |
|
8,550 |
7,975 |
$41K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
19,716 |
17,809 |
$40K |
| 86762 |
|
5,430 |
5,080 |
$37K |
| 86901 |
|
6,566 |
6,122 |
$37K |
| 87340 |
|
5,321 |
4,994 |
$36K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
280 |
150 |
$34K |
| 77336 |
|
863 |
359 |
$34K |
| 36415 |
Collection of venous blood by venipuncture |
15,485 |
12,544 |
$32K |
| 81025 |
|
10,170 |
9,522 |
$32K |
| 87275 |
|
8,550 |
7,975 |
$29K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
66 |
37 |
$28K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
389 |
317 |
$26K |
| 77334 |
|
152 |
103 |
$24K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
550 |
459 |
$24K |
| 83605 |
|
4,001 |
3,629 |
$22K |
| 11043 |
|
297 |
186 |
$19K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
692 |
638 |
$19K |
| 87081 |
|
4,253 |
4,099 |
$18K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,114 |
1,414 |
$17K |
| 71046 |
Radiologic examination, chest; 2 views |
1,442 |
1,338 |
$17K |
| 81001 |
|
20,601 |
19,085 |
$16K |
| 84703 |
|
3,882 |
3,692 |
$13K |
| 83615 |
|
2,628 |
2,148 |
$12K |
| 84460 |
|
2,724 |
2,307 |
$12K |
| 87186 |
|
1,681 |
1,540 |
$12K |
| 84450 |
|
2,721 |
2,305 |
$12K |
| 87147 |
|
1,070 |
941 |
$12K |
| 84520 |
|
2,219 |
1,845 |
$10K |
| 84550 |
|
2,663 |
2,174 |
$9K |
| 82565 |
|
1,425 |
1,196 |
$9K |
| 85610 |
|
4,670 |
4,298 |
$8K |
| 85027 |
|
1,874 |
1,747 |
$8K |
| J1756 |
Injection, iron sucrose, 1 mg |
543 |
192 |
$7K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
170 |
152 |
$7K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
126 |
110 |
$6K |
| 81003 |
|
8,489 |
7,915 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,574 |
1,326 |
$6K |
| 84134 |
|
1,315 |
1,227 |
$6K |
| 82077 |
|
2,164 |
1,930 |
$6K |
| 96417 |
|
120 |
62 |
$5K |
| 77300 |
|
48 |
42 |
$5K |
| 82947 |
|
960 |
914 |
$5K |
| 80061 |
Lipid panel |
1,201 |
1,120 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
195 |
187 |
$4K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
195 |
187 |
$4K |
| 82570 |
|
776 |
650 |
$4K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
84 |
83 |
$4K |
| 84466 |
|
968 |
903 |
$4K |
| 82607 |
|
605 |
582 |
$4K |
| 84156 |
|
1,864 |
1,548 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
54 |
50 |
$3K |
| 83540 |
|
1,228 |
1,157 |
$3K |
| 84439 |
|
446 |
421 |
$3K |
| 85730 |
|
602 |
568 |
$3K |
| J1453 |
Injection, fosaprepitant, 1 mg |
21 |
12 |
$3K |
| 74246 |
|
70 |
70 |
$2K |
| 84425 |
|
245 |
230 |
$2K |
| 82575 |
|
285 |
274 |
$2K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
64 |
12 |
$2K |
| 83735 |
|
701 |
645 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,470 |
917 |
$2K |
| 82746 |
|
454 |
440 |
$2K |
| 77280 |
|
16 |
12 |
$2K |
| 87077 |
|
348 |
319 |
$2K |
| 82731 |
|
53 |
49 |
$2K |
| 77290 |
|
16 |
14 |
$1K |
| 87040 |
|
147 |
129 |
$1K |
| 85014 |
|
945 |
841 |
$1K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
125 |
93 |
$1K |
| 80076 |
|
437 |
390 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
246 |
240 |
$1K |
| 96367 |
|
58 |
39 |
$1K |
| 84481 |
|
67 |
62 |
$993.18 |
| 82550 |
|
314 |
287 |
$969.25 |
| 83970 |
|
70 |
65 |
$866.31 |
| 96415 |
|
20 |
12 |
$857.07 |
| 74240 |
|
30 |
26 |
$798.55 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
29 |
25 |
$781.90 |
| 87522 |
Neg quan hep c or qual rna |
29 |
25 |
$579.75 |
| 87205 |
|
320 |
257 |
$572.85 |
| 87210 |
|
182 |
178 |
$538.12 |
| 87088 |
|
82 |
80 |
$522.19 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
162 |
145 |
$497.63 |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
29 |
25 |
$439.95 |
| 82553 |
|
242 |
223 |
$396.45 |
| 85379 |
|
56 |
52 |
$383.78 |
| 87070 |
|
294 |
242 |
$375.53 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
14 |
13 |
$307.88 |
| 87075 |
|
120 |
92 |
$131.84 |
| 84145 |
|
14 |
13 |
$81.21 |
| 80177 |
|
16 |
15 |
$61.74 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
14 |
13 |
$58.95 |
| 73562 |
|
13 |
12 |
$58.68 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
25 |
25 |
$13.74 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,597 |
5,202 |
$8.44 |
| 84100 |
|
12 |
12 |
$3.25 |
| A9270 |
Non-covered item or service |
3,816 |
3,181 |
$0.77 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,419 |
1,352 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
292 |
270 |
$0.00 |
| 74022 |
|
19 |
15 |
$0.00 |